Reactions 1680, p22 - 2 Dec 2017 Drug eruption and lymphopenia: case report A 32-year-old woman developed drug eruption and lymphopenia during treatment with alemtuzumab [route and dosage not sated]. The woman, who had a history of multiple sclerosis, started receiving treatment with alemtuzumab for three days as per the protocol. After 10 days of initiation of alemtuzumab, she experienced a widespread rash. Laboratory tests showed elevated CRP (67 mg/L) and lymphopenia (lymphocytes 0.2 × 10 /L) which is an expected adverse effect of alemtuzumab. A diagnosis of a drug eruption secondary to alemtuzumab was made. The authors considered drug eruption to be serious. The woman started receiving treatment with steroids and prednisolone. She responded well to the treatment. She recovered completely, and 12 months later, she received different treatment. The treatment with alemtuzumab was restarted. She again developed skin erythema on her forearms and thighs, which resolved immediately. Author comment: "[T]his case of a severe blistering drug eruption secondary to alemtuzumab in a patient who also had a successful re-exposure, is the first reported." Ngu S, et al. A case of severe drug reaction secondary to alemtuzumab with successful re-exposure. Clinical and Experimental Dermatology 42: 925-926, No. 8, Dec 2017. Available from: URL: http://doi.org/10.1111/ced.13230 - United Kingdom 803284975 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera